ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Markets

Moderna leads all drugmakers in market-cap gain during COVID

Razor focus on cutting-edge technology gives new players an edge

Vials of Moderna's COVID-19 vaccine in Toronto. The company's investment in mRNA technology has paid off handsomely.   © Reuters

TOKYO -- Moderna has increased its valuation more than any other drugmaker in the world during the pandemic as new opportunities arising from the coronavirus boost sharp-focused newcomers to new heights.

Moderna's market capitalization rose by more than $130 billion between the end of September and Thursday to nearly $140 billion, according to a ranking compiled by QUICK-FactSet.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more